Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as...

Area of Science:

• Medicinal Chemistry
• Organic Synthesis
• Cancer Biology

Background:

• Targeting the B-Raf kinase is crucial for treating certain cancers, particularly melanoma.
• Developing selective and potent B-Raf inhibitors with low toxicity remains a significant challenge.

Purpose of the Study:

• To synthesize novel dioxin-containing triaryl pyrazoline derivatives.
• To evaluate their B-Raf inhibitory and anti-proliferation activities.
• To explore structure-activity relationships for optimized drug design.

Main Methods:

• Synthesis of 20 novel dioxin-containing triaryl pyrazoline derivatives (C1-C20).
• In vitro evaluation of B-Raf inhibitory activity and anti-proliferation effects on melanoma cell lines.
• Selectivity profiling against B-Raf(WT), C-Raf, and EGFR.
• Molecular docking simulations and 3D Quantitative Structure-Activity Relationship (QSAR) modeling.

Main Results:

• Compound C6 exhibited potent B-Raf(V600E) inhibition (IC50 = 0.04 μM) and anti-proliferative activity against WM266.4 melanoma cells (GI50 = 0.87 μM).
• C6 demonstrated selectivity for B-Raf(V600E) over B-Raf(WT), C-Raf, and EGFR, with low observed toxicity.
• Docking studies suggested a novel binding interaction mode for C6.
• A 3D QSAR model was developed to guide future structural modifications.

Conclusions:

• Compound C6 represents a highly potent and selective B-Raf inhibitor with potential for melanoma treatment.
• The novel binding pattern and QSAR model provide valuable insights for designing next-generation kinase inhibitors.
• Future research should explore structural modifications, such as backbone stretching or reversal, to further enhance activity and selectivity.